Jeffrey Lawrence Schwartz is Director at SpringWorks Therapeutics, Inc. (SWTX). They have made 2 open-market trades across 2 companies since 2023, most recently 2026-09-09.
CIK 0001702957
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SWTX | 10,572 | $497K |
| KMTS | 14,236 | $387K |
| RPID | 14,300 | $11K |
| BLSA | 487,500 | — |
| Total | $894K |
Shares reported on the most recent Form 4, priced at the 2026-09-10 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.